ArticleAnnals of medicine2026
Efficacy of atopic dermatitis alleviation through transcutaneous auricular vagus nerve stimulation in 2,4-dinitrochlorobenzene (DNCB)-induced mouse model.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) commonly begins in early childhood, and non-pharmacological treatment options remain limited. Vagal cholinergic signaling can modulate immune responses, suggesting a potential role for neuromodulation in inflammatory skin disease. This study investigated whether transcutaneous auricular vagus nerve stimulation (taVNS) alleviates AD-like skin inflammation and whether acetylcholine receptor signaling contributes to its effects.
methodsAD-like dermatitis was induced in BALB/c mice using 2,4-dinitrochlorobenzene (DNCB). taVNS (0.2 mA, 15 Hz for 5 min) was applied every 2-3 days for 1 or 2 weeks. Histopathology changes and inflammatory marker expression were assessed in lesional skin. To explore the underlying mechanism, acetylcholine receptor antagonism was used.
resultstaVNS improved histological features and reduced inflammatory markers compared with DNCB alone. These effects were partially attenuated by acetylcholine receptor antagonism, suggesting involvement of cholinergic signaling, including α7 nicotinic acetylcholine receptors.
conclusiontaVNS may be a promising non-invasive adjunctive approach for AD. Its anti-inflammatory effects appear to be associated, at least in part, with cholinergic signaling pathways, warranting further mechanistic and translational studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.